Investigation Potential Antidiabetic Activity of Angelica gigas Nakai Leaf Extract

Abstract

This study was conducted to investigate Angelica gigas Nakai leaf extract (ALE) as an antidiabetic. The inhibitory activity of ALE on α-glucosidase inhibition and rat intestinal disaccharidase were measured. Also, its effect on glucose uptake in 3T3-L1 cells was analyzed. Supplementation of ALE up to 150µg/mL showed cell viability higher than 90% in 3T3-L1 cells. The 60% and 80% of ethanol ALE revealed the highest α-glucosidase inhibitory activity. Further, the 60% ethanol ALE extracts were freeze-dried (FD60) and spray-dried (SD60) to evaluate their antidiabetic effects. The α-glucosidase inhibitory assay revealed that the IC50 of SD60 and FD60 were 4.08 mg/mL and 2.93 mg/mL, respectively. A Lineweaver-Burk plot showed that ALE demonstrates mixed-type inhibition. FD60 and SD60 showed no significant difference in inhibiting maltase, sucrase, and glucoamylase of rat intestinal disaccharidase. FD60 and SD60 significantly (p < 0.05) increased insulin-stimulated glucose uptake in 3T3-L1 cells compared to D-pinitol. Moreover, ALE could increase the expression of pAkt Thr308 in Vero 76 cells via western blot analysis. These findings suggest that ALE has potential antidiabetic properties.